Suven Pharmaceuticals Ltd.(IN:COHANCE)
₹456.40+4.75 (+1.05%)
IN:COHANCE
Suven Pharmaceuticals Ltd. Revenue
₹456.40
At close:+4.75 (+1.05%)
Want to see IN:COHANCE full AI Analyst Report?
Suven Pharmaceuticals Ltd. (COHANCE) Revenue
3 Followers
Suven Pharmaceuticals Ltd. Revenue
Suven Pharmaceuticals Ltd. had a revenue of 4.77B in the quarter ending Sep 30, 2026, with 12.88%. This bring the company's revenue in the last twelve months to 20.63B, Decreased 3.69%. In the fiscal year ending Mar 31, 2026, Suven Pharmaceuticals Ltd. had annual revenue of 22.69B with 89.43% growth.
- Revenue (ttm)
- 20.63B
- Revenue Growth
- 13.70%
- P/S Ratio
- 7.62
- Revenue/Employee
- INR 19,015,507
- Employees
- 1,193
- Market Cap
- INR 172.80B
Revenue Chart
Suven Pharmaceuticals Ltd. Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 22.69B | 10.71B | 89.43% |
| Mar 31, 2025 | 11.98B | 1.46B | 13.91% |
| Mar 31, 2024 | 10.51B | -2.89B | -21.56% |
| Mar 31, 2023 | 13.40B | 201.07M | 1.52% |
| Mar 31, 2022 | 13.20B | 3.11B | 30.75% |
| Mar 31, 2021 | 10.10B | 1.76B | 21.10% |
| Mar 31, 2020 | 8.34B | -730.13M | -8.05% |
| Mar 31, 2019 | 9.07B | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company | Revenue |
|---|---|
| IN:COHANCE | 20.63B |
| IN:GRANULES | 58.83B |
| IN:JUBLPHARMA | 86.08B |
| IN:LAURUSLABS | 78.23B |
| IN:NEULANDLAB | 23.07B |
| IN:SOLARA | 15.35B |

